title: Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
authors.forename: D C
authors.initials: DC
authors.lastname: Phillips
authors.forename: Y
authors.initials: Y
authors.lastname: Xiao
authors.forename: L T
authors.initials: LT
authors.lastname: Lam
authors.forename: E
authors.initials: E
authors.lastname: Litvinovich
authors.forename: L
authors.initials: L
authors.lastname: Roberts-Rapp
authors.forename: A J
authors.initials: AJ
authors.lastname: Souers
authors.forename: J D
authors.initials: JD
authors.lastname: Leverson